Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 309

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance

Open access
Yamazaki, Chisato M., Yamaguchi, Aiko, Anami, Yasuaki, Xiong, Wei, Otani, Yoshihiro, Lee, Jangsoon, Ueno, Naoto T., Zhang, Ningyan, An, Zhiqiang, Tsuchikama, Kyoji·2021·Nature Communications

Abstract

Breast tumors generally consist of a diverse population of cells with varying gene expression profiles. Breast tumor heterogeneity is a major factor contributing to drug resistance, recurrence, and metastasis after chemotherapy. Antibody-drug conjugates (ADCs) are emerging chemotherapeutic agents with striking clinical success, including T-DM1 for HER2-positive breast cancer. However, these ADCs often suffer from issues associated with intratumor heterogeneity. Here, we show that homogeneous ADCs containing two distinct payloads are a promising drug class for addressing this clinical challenge. Our conjugates show HER2-specific cell killing potency, desirable pharmacokinetic profiles, minimal inflammatory response, and marginal toxicity at therapeutic doses. Notably, a dual-drug ADC exerts greater treatment effect and survival benefit than does co-administration of two single-drug variants in xenograft mouse models representing intratumor HER2 heterogeneity and elevated drug resistance. Our findings highlight the therapeutic potential of the dual-drug ADC format for treating refractory breast cancer and perhaps other cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-23793-7

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 309

Metadata

Authors
Yamazaki, C. M., Yamaguchi, A., Anami, Y., Xiong, W., Otani, Y., Lee, J., Ueno, N. T., Zhang, N., An, Z., & Tsuchikama, K.
Venue
Nature Communications
Published
2021-06-10
Volume
12
Issue
1
Pages
3528-3528
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3167756601
Cited by
309
References
52
FWCI
13.53
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. https://app.cochat.ai/papers/10.1038/s41467-021-23793-7
The paper
Yamazaki, C. M., Yamaguchi, A., Anami, Y., Xiong, W., Otani, Y., Lee, J., Ueno, N. T., Zhang, N., An, Z., & Tsuchikama, K. (2021). Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nature Communications. https://doi.org/10.1038/s41467-021-23793-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.